Akero Therapeutics, Inc. (NASDAQ:AKRO) COO Jonathan Young Sells 5,000 Shares

Akero Therapeutics, Inc. (NASDAQ:AKRO) COO Jonathan Young sold 5,000 shares of the company’s stock in a transaction on Monday, July 1st. The shares were sold at an average price of $23.40, for a total transaction of $117,000.00. Following the completion of the sale, the chief operating officer now owns 246,854 shares of the company’s stock, valued at approximately $5,776,383.60. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.

Jonathan Young also recently made the following trade(s):

• On Tuesday, June 11th, Jonathan Young sold 2,516 shares of Akero Therapeutics stock. The shares were sold at an average price of $22.64, for a total transaction of $56,962.24.
• On Monday, June 3rd, Jonathan Young sold 5,000 shares of Akero Therapeutics stock. The stock was sold at an average price of $19.29, for a total transaction of $96,450.00.
• On Wednesday, May 1st, Jonathan Young sold 5,000 shares of Akero Therapeutics stock. The shares were sold at an average price of $20.15, for a total value of $100,750.00.

Akero Therapeutics Stock Performance

Shares of AKRO opened at $22.38 on Wednesday. The company has a quick ratio of 30.12, a current ratio of 30.12 and a debt-to-equity ratio of 0.04. Akero Therapeutics, Inc. has a 52-week low of $11.25 and a 52-week high of $53.77. The company has a 50-day simple moving average of $21.08 and a 200-day simple moving average of $22.69. The company has a market capitalization of $1.55 billion, a PE ratio of -6.99 and a beta of -0.28.

Akero Therapeutics (NASDAQ:AKRO) last issued its earnings results on Friday, May 10th. The company reported ($0.90) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.90). Equities research analysts predict that Akero Therapeutics, Inc. will post -3.82 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Akero Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of AKRO. Janus Henderson Group PLC grew its holdings in Akero Therapeutics by 42.2% in the first quarter. Janus Henderson Group PLC now owns 6,121,970 shares of the company’s stock valued at $154,589,000 after purchasing an additional 1,815,569 shares during the last quarter. Price T Rowe Associates Inc. MD boosted its position in shares of Akero Therapeutics by 10.5% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 4,060,479 shares of the company’s stock worth $102,569,000 after buying an additional 384,555 shares in the last quarter. Vanguard Group Inc. grew its stake in Akero Therapeutics by 19.0% in the 1st quarter. Vanguard Group Inc. now owns 3,669,923 shares of the company’s stock valued at $92,702,000 after acquiring an additional 584,875 shares during the last quarter. RTW Investments LP purchased a new position in Akero Therapeutics during the 4th quarter valued at about $83,891,000. Finally, Wellington Management Group LLP raised its position in Akero Therapeutics by 247.7% during the fourth quarter. Wellington Management Group LLP now owns 2,881,989 shares of the company’s stock worth $67,294,000 after acquiring an additional 2,053,028 shares during the last quarter.

Analyst Ratings Changes

Several research analysts have weighed in on the company. UBS Group lifted their target price on Akero Therapeutics from $39.00 to $42.00 and gave the company a “buy” rating in a research note on Tuesday, March 5th. Cantor Fitzgerald reissued an “overweight” rating on shares of Akero Therapeutics in a research note on Thursday, June 20th. Bank of America began coverage on shares of Akero Therapeutics in a research note on Monday, April 22nd. They issued a “neutral” rating and a $30.00 target price for the company. Canaccord Genuity Group dropped their price target on shares of Akero Therapeutics from $59.00 to $56.00 and set a “buy” rating on the stock in a research note on Monday, May 13th. Finally, Evercore ISI reduced their price objective on shares of Akero Therapeutics from $50.00 to $38.00 and set an “outperform” rating for the company in a research report on Wednesday, May 15th. One investment analyst has rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $41.13.

About Akero Therapeutics

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.